Latest Nasdaq News

IperionX has landed a second U.S. Army task order worth US$11.5 million to expand its industrial-scale titanium manufacturing capacity in Virginia, advancing its integrated powder-to-part platform for defense applications.

Red Mountain Mining has kicked off its first reverse circulation drilling campaign at the Armidale Antimony-Gold Project in NSW, aiming to test high-grade orogenic antimony-gold mineralisation at the Oaky Creek prospect. Seventeen holes are planned over three weeks, with assay results expected next quarter.

European Lithium has lodged the Scheme Booklet with ASIC for its proposed merger with Critical Metals Corp, advancing the regulatory process with a court hearing scheduled for mid-September.

Almonty Industries will voluntarily delist from the ASX by September 1, 2026, consolidating its trading on Nasdaq and Frankfurt amid strategic shifts in its market presence.

Immuron Limited posted a 6% rise in FY26 sales to $7.7 million, improved its net loss by $1.4 million, and secured FDA approval for IMM-529, underpinning a strategic pivot towards profitability and geographic expansion.

Elevra Lithium posted a $44 million profit in FY26 after merging Sayona Mining and Piedmont Lithium, overcoming temporary mining challenges and securing full funding for the North American Lithium expansion.

Pengana Private Equity Trust (ASX: PE1) posted a 23.2% net return for FY2026, powered by a dramatic revaluation of SpaceX and strong gains across a diversified private equity portfolio.

Clinuvel Pharmaceuticals marked its tenth consecutive profit with stable revenues and rising cash reserves, while accelerating U.S. expansion including a Nasdaq uplisting and potential ASX delisting.

Radiopharm Theranostics has dosed the first patient in the second cohort of its Phase 1/2a trial for RV-01, a radiopharmaceutical targeting B7-H3 expressing solid tumors, marking a key dose escalation milestone.

Veris Limited lifted revenue by 4.9% to $102 million in FY26, driven by digital and advisory growth, but statutory net profit fell 67% amid one-off costs and macroeconomic headwinds.

Neuren Pharmaceuticals’ partner Acadia Pharmaceuticals secured European Commission approval for DAYBU (trofinetide) to treat Rett syndrome symptoms in patients aged five and older, marking the first EU-authorised treatment for this condition.

Elevra Lithium has secured a binding seven-year supply agreement with Mangrove Lithium for spodumene concentrate from its North American Lithium site, anchoring a key feedstock for Mangrove’s planned Canadian lithium conversion facility.